US 12,465,591 B2
Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
Sun Gwan Hwang, Gyeonggi-do (KR); and Ji Won Lee, Gyeonggi-do (KR)
Assigned to SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-Do (KR)
Appl. No. 17/286,529
Filed by SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
PCT Filed Oct. 18, 2019, PCT No. PCT/KR2019/013701
§ 371(c)(1), (2) Date Apr. 19, 2021,
PCT Pub. No. WO2020/080866, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,841, filed on Oct. 19, 2018.
Prior Publication US 2021/0379018 A1, Dec. 9, 2021
Int. Cl. A61K 31/41 (2006.01); A61P 25/02 (2006.01); A61P 25/04 (2006.01)
CPC A61K 31/41 (2013.01) [A61P 25/02 (2018.01); A61P 25/04 (2018.01)] 9 Claims
 
1. A method for alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy, comprising:
administering to a subject in need thereof a therapeutically effective amount of a carbamate compound which is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl-ethyl ester of the following Formula 2, or a pharmaceutically acceptable salt or hydrate thereof:

OG Complex Work Unit Chemistry